Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Learn about the best cash back rewards cards that come with no fees. Maximize your benefits today!
23,366 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
The market is hovering around record levels, but does that mean you should sit on the sidelines? Not necessarily. Thi...
In the first half of 2026, Sandisk towered over the S&P 500. This article explains the drivers behind that outperform...
SoFi stock has dipped back toward the $18 area, prompting questions about a long-awaited recovery. This guide breaks ...
A notable stake increase in Shift4 Payments hints at growing conviction from Maestria Partners. This deep dive explai...
AI investing can take two paths: a targeted, actively managed approach with CHAT or a broad, low-cost tech track with...
A surprising 90% rally in a little-known healthcare stock has investors asking what comes next. This guide breaks dow...
A voluntary recall of thousands of Waymo AVs grabbed headlines, but the bigger story is the decade ahead for autonomo...
Two AI stocks carry consensus upside targets of 47% and 54%. This guide explains what drives those bets and how to ev...
Micron's memory leadership and AI-ready HBM4 shipments clash with Intel's restructuring effort and foundry bets. As A...
SoundHound AI is testing a high-growth path in voice commerce and Vision AI. This article explains why some investors...
The chatter around a SpaceX IPO has investors buzzing, but hype can blur fundamentals. This guide breaks down what to...